Company intelligence / Profile preview

Shengyin Biopharmaceutical

Ownership: Private
Development stage: Other

Overview

Shengyin Biopharmaceutical is a clinical-stage biotechnology company based in China that specializes in the development of small interfering RNA (siRNA) therapeutics. The company leverages its proprietary GalNAc-based delivery platform to target liver-expressed genes involved in metabolic and cardiovascular diseases. Its lead programs focus on chronic conditions such as hypertriglyceridemia and hypercholesterolemia, aiming to provide long-acting treatments that improve patient compliance. Shengyin is actively advancing a robust pipeline of RNAi candidates through early-stage clinical trials in both China and international markets.

Therapeutic areas: CardiovascularMetabolic Disorders
Modalities: Small interfering RNARNA therapyLipid nanoparticle delivery therapy
Industry: Biotech

Drug pipeline

1 asset

SGB-3252

Preclinical

Beyond the preview

Go deeper on Shengyin Biopharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shengyin Biopharmaceutical.